First Dallas Securities Inc. bought a new position in shares of GlaxoSmithKline plc (NYSE:GSK) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,015 shares of the pharmaceutical company’s stock, valued at approximately $142,000.
Several other hedge funds have also recently bought and sold shares of GSK. Gotham Asset Management LLC grew its holdings in shares of GlaxoSmithKline by 4.3% during the 2nd quarter. Gotham Asset Management LLC now owns 26,495 shares of the pharmaceutical company’s stock worth $1,142,000 after acquiring an additional 1,103 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of GlaxoSmithKline by 18.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,960 shares of the pharmaceutical company’s stock worth $818,000 after acquiring an additional 2,968 shares during the period. Nomura Holdings Inc. purchased a new position in shares of GlaxoSmithKline during the 2nd quarter worth approximately $265,000. 1st Global Advisors Inc. grew its holdings in shares of GlaxoSmithKline by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after acquiring an additional 19 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of GlaxoSmithKline during the 2nd quarter worth approximately $290,000. Hedge funds and other institutional investors own 9.52% of the company’s stock.
A number of research analysts have weighed in on the company. Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. TheStreet cut GlaxoSmithKline from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. Kepler Capital Markets raised GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Friday. Investec cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, February 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the company’s stock. GlaxoSmithKline has an average rating of “Hold” and an average price target of $38.57.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.03. The business had revenue of $10.14 billion for the quarter, compared to analysts’ expectations of $9.89 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. equities analysts anticipate that GlaxoSmithKline plc will post 2.82 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Investors of record on Friday, February 23rd will be given a $0.633 dividend. The ex-dividend date of this dividend is Thursday, February 22nd. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 annualized dividend and a yield of 6.94%. GlaxoSmithKline’s dividend payout ratio is 258.23%.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.